

09-06-02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Debra D. Pittman, et al.

Serial No: 10/023,451

Filed: December 17, 2001

For: *Methods and Compositions for  
Diagnosing and Treating Rheumatoid  
Arthritis*

Examiner: To be assigned

Art Unit: 1615

Attorney Docket No. GIA-00.01

RECEIVED  
SEP 12 2002  
TECH CENTER 1600/2301  
6  
BD  
9-16-02



**Certificate Of Express Mail**

I hereby certify that this Request for Correction of Filing Receipt is being deposited with the United States Postal Service as Express Mail No. EV117996914US, postage prepaid, "Post Office to Addressee", in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

September 5, 2002

Date of Mailing

*Terrell Williams*  
Terrell Williams

Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97(b)**

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § § 1.56 and 1.97(b)(3).

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.


This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each of the listed documents is material or constitutes "prior art." If the Examiner applies any of the listed documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more documents be applied against the claims of the present application.

If an Office Action on the merits is mailed out prior to reception of this IDS, the Commissioner is hereby allowed to charge the amount of \$180.00 to our Deposit Account No. 06-1448, to cover the fee required by 37 C.F.R. § 1.97 (c). The Commissioner is also authorized to charge any fee deficiencies and credit any overpayment to our Deposit Account No. 06-1448.

Respectfully Submitted,

**Customer No: 25181**  
Patent Group  
Foley Hoag LLP  
155 Seaport Boulevard  
Boston, MA 02210-2600  
Tel. (617) 832-1000  
Fax. (617) 832-7000  
Date: September 5, 2002

By:   
Isabelle Clauss  
Reg. No. 47,326  
Attorney for Applicants

Form PTO-1449

**INFORMATION DISCLOSURE CITATION**

**IN AN APPLICATION**  
(Use several sheets if necessary)

Docket Number (Optional)

GIA-001.01

Application Number

10/023,441

Applicant  
Pittman et al.Filing Date  
December 17, 2002Group Art Unit  
1615**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	BA						

**OTHER DOCUMENTS**

(Including Author, Title, Date, Pertinent Pages Etc.)

CA	Gu, J. et al. (2001), <i>Analysis of Inflammation Related Gene Expression Spectrum in Ankylosing pondylitis Patients Using cDNA Microarray</i> (Abstract only), ZHONGHUA YI XUE ZA ZHI 81(17):1030.
CB	Zanders, E. D. et al. (2000), <i>Analysis of Immune System Gene Expression in Small Rheumatoid Arthritis Biopsies Using a Combination of Subtractive Hybridization and High-Density cDNA Arrays</i> , J. IMMUNOL. METHODS 233(1-2):131.
CC	Heller, R.A. et al. (1997), <i>Discovery and Analysis of Inflammatory Disease-Related Genes Using cDNA Microarrays</i> , PROC. NATL. ACAD. SCI. USA 94(6):2150.
CD	Moriguchi, M. et al. (1999), <i>Influence of Genotypes at SAA1 and SAA2 loci on the Development and the Length of Latent Period of Secondary AA-Amyloidosis in Patients with Rheumatoid Arthritis</i> , HUM. GENET. 105(4):360.
CE	Booth, D.R. et al. (1998), <i>SAA1 Alleles as Risk Factors in Reactive Systemic AA Amyloidosis</i> , AMYLOID 5(4):262.
CF	Kumon, Y. et al. (1997), <i>Rheumatoid Arthritis Exhibits Reduced Acute Phase and Enhanced Constitutive Serum Amyloid A Protein in Synovial Fluid Relative to Serum</i> , J. RHEUMATOL. 24(1):14.
CG	Ducret, A. et al. (1996), <i>Characterization of Human Serum Amyloid A Protein Isoforms Separated by Two-Dimentional Electrophoresis by Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry</i> , ELECTROPHORESIS 17(5):866.
CH	Baba, S. et al. (1992), <i>Identification of Two Novel Amyloid A Protein Subsets Coexisting in an Individual Patient of AA-Amyloidosis</i> , BIOCHEM. BIOPHYS. ACTA. 1180(2):195.
CI	Yamada, T. et al. (1998), <i>The Frequency of Serum Amyloid A2 Alleles in the Japanese Population</i> , AMYLOID 5(3):208.

## INFORMATION DISCLOSURE CITATION

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)

GIA-001.01

Application Number

10/023,451

Applicant  
Shuman et al.Filing Date  
December 19, 2002

Group Art Unit

1615

- Linke, R.P. et al. (1991), *Inhibition of the Oxidative Burst Response of N-Formyl Peptide-Stimulated Neutrophils by Serum Amyloid-A Protein*, BIOCHEM. BIOPHYS. RES. COMMUN. 176(3):1100.
- Rosenberg, A.M. et al. (2000), *Relationship Between Sex and Antibodies to High Mobility Group Proteins 1 and 2 in Juvenile Idiopathic Arthritis*, J. RHEUMATOL. 27(10):2489.
- Uesugi, H. et al. (1998), *Prevalence and Characterization of Novel pANCA, Antibodies to the High Mobility Group Non-Histone Chromosomal Proteins HMG1 and HMG2, in Systemic Rheumatic Diseases*, J. RHEUMATOL. 25(4):703.
- Witemann, B. et al. (1990), *Autoantibodies to Nonhistone Chromosomal Proteins HMG-1 and HMG-2 in Sera of Patients with Juvenile Rheumatoid Arthritis*, ARTHRITIS RHEUM. 33(9):1378.
- Kerkoff, C. et al. (1998), *Novel Insights into Structure and unction of MRP8 (S100A8) and MRP14 (S100A9)*, BIOCHEM. BIOPHYS. ACTA. 1448(2):200.
- Ekerot, L. et al. (1983), *Protease Inhibitors in Rheumatoid Synovial Fluid: A Quantitative Analysis*, CLIN. EXP. RHEUMATOL. 1(3):225.
- Tanaka, M. et al. (1998), *Cloning of Follistatin-Related Protein as a Novel Autoantigen in Systemic Rheumatic Diseases*, INT. IMMUNOL. 10(9):1305.
- McDevitt, H. (2000), *A New Model for Rheumatoid Arthritis?*, ARTHRITIS RES. 2(2):85.
- Kyburz, D. et al. (2000), *The Role of CD40 Ligand and Tumor Necrosis Factor Alpha Signaling in the Transgenic K/BxN Mouse Model of Rheumatoid Arthritis*, ARTHRITIS RHEUM. 43(11):2571.
- Matsumoto, I. et al. (1999), *Arthritis Provoked by Linked T and B Cell Recognition of a Glycolytic Enzyme*, SCIENCE 286(5445):1732.
- Wisniewski, H.G. et al. (1996), *TNF/IL-1-Inducible Protein TSG-6 Potentiates Plasmin Inhibition by Inter-Alpha-Inhibitor and Exerts a Strong Anti-Inflammatory Effect in Vivo*, J. IMMUNOL. 156(4):1609.
- Larbre, J.P. et al. (1994), *Direct Degradation of Articular Cartilage by Rheumatoid Synovial Fluid: Contribution of Proteolytic Enzymes*, J. RHEUMATOL. 21(10):1796.
- Froelich, C.J. et al. (1993), *Human Granzyme B Degrades Aggrecan Proteoglycan in Matrix Synthesized by Chondrocytes*, J. IMMUNOL. 151(12):7161.
- Mindrescu, C. et al. (2000), *Amelioration of Collagen-Induced Arthritis in DBA/1J Mice by Recombinant TSG-6, a Tumor Necrosis Factor/Interleukin-1-Inducible Protein*, ARTHRITIS RHEUM. 43(12):2668.
- Fulop, C. et al. (1997), *Coding sequence, Exon-Intron Structure and Chromosomal Localization of Murine TNF-Stimulated Gene 6 That is Specifically Expressed by Expanding Cumulus Cell-Oocyte Complexes*, GENE 202(1-2):95.
- Wisniewski, H.G. et al. (1994), *TSG-6, an Arthritis-Associated Hyaluronan Binding Protein, Forms a Stable Complex with the Serum Protein Inter-Alpha-Inhibitor*, BIOCHEM. 33(23):7423.
- Wisniewski, H.G. et al. (1993), *TSG-6: a TNF-, IL-1-, and LPS-Inducible Secreted Glycoprotein Associated with Arthritis*, J. IMMUNOL. 151(11):6593.

Form PTO-1449

## INFORMATION DISCLOSURE CITATION

## IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)  
GIA-001.01Application Number  
10/023,451Applicant  
Pittman et al.Filing Date  
December 17, 2002

Group Art Unit

1615

SEP 05 2002

AUG 05 2002

RECEIVED  
SEP 12 2002

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE